Table 1 Demographic characteristics of patients eligible for anti-TNF therapy
Variable | Value |
|---|---|
Patients, n | 77 |
Male/female, n | 42/35 |
Average age, years, n (SD) | 55.3 (12.5) |
Rheumatoid arthritis patients, n (%) | 36 (46.8) |
Psoriatic arthritis patients, n (%) | 24 (31.2) |
Ankylosing spondylitis patients, n (%) | 17 (22.1) |
DMARDs intake, n (%) | 55 (71.4) |
Methotrexate, n (%) | 31 (56.4) |
Cyclosporin, n (%) | 10 (18.0) |
Leflunomide, n (%) | 4 (7.0) |
Steroids intake, n (%) | 12 (15.6) |
Anti-TNF intake, n (%) | 75 (97.4) |
Infliximab, n (%) | 38 (51.0) |
Adalimumab, n (%) | 19 (25.0) |
Etanercept, n (%) | 18 (24.0) |
Antinuclear antibodies positivity, n (%)* | 10 (13.0) |
Rheumatic factor positivity, n (%)* | 28 (36.4) |
Anti-citrullinated antibodies positivity, n (%)* | 29 (37.7) |